Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.
OBJECTIVE
To document a case of serotonin syndrome associated with venlafaxine and fluoxetine that did not involve a monoamine oxidase inhibitor, and to examine the multiple factors, including pharmacodynamic and pharmacokinetic interactions, that likely caused this adverse drug reaction (ADR).


METHODS
A 39-year-old white woman with depression and panic attacks was being treated with fluoxetine, trazodone, clonazepam, and cimetidine. After fluoxetine and clonazepam were abruptly discontinued, venlafaxine and lorazepam were started. Within 24 hours, she developed diaphoresis, tremors, slurred speech, myoclonus, restlessness, impaired thinking, and diarrhea. This constellation meets Sternbach's criteria for serotonin syndrome.


CONCLUSIONS
The possible contributors to this ADR are discussed, including a single drug effect (e.g., an idiosyncratic reaction to venlafaxine), a pharmacokinetic interaction, a pharmacodynamic interaction, a combined pharmacokinetic-pharmacodynamic interaction, and the patient' s panic disorder.


CONCLUSIONS
As more serotonergic drugs are developed and used for psychiatric disorders, frequently in combination or close temporal proximity, clinicians must be aware of and consider the factors that may increase the risk of patients experiencing serotonin syndrome.
Bhatara
V S
VS
Child Psychiatry, University of South Dakota School of Medicine, Sioux Falls, USA.
Magnus
R D
RD
Paul
K L
KL
Preskorn
S H
SH
D000328:Adult; D003511:Cyclohexanols / Q000009:adverse effects* / Q000493:pharmacokinetics; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D016584:Panic Disorder / Q000150:complications / Q000188:drug therapy; D012701:Serotonin / Q000502:physiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D005473:Fluoxetine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride